Radiation therapy or radiotherapy is a treatment using ionizing radiation, generally provided as part of cancer therapy to either kill or control the growth of malignant cells. It is normally delivered by a linear particle accelerator. Radiation therapy may be curative in a number of types of cancer if they are localized to one area of the body, and have not spread to other parts. It may also be used as part of adjuvant therapy, to prevent tumor recurrence after surgery to remove a primary malignant tumor. Radiation therapy is synergistic with chemotherapy, and has been used before, during, and after chemotherapy in susceptible cancers. The subspecialty of oncology concerned with radiotherapy is called radiation oncology. A physician who practices in this subspecialty is a radiation oncologist.
A tumor suppressor gene (TSG), or anti-oncogene, is a gene that regulates a cell during cell division and replication. If the cell grows uncontrollably, it will result in cancer. When a tumor suppressor gene is mutated, it results in a loss or reduction in its function. In combination with other genetic mutations, this could allow the cell to grow abnormally. The loss of function for these genes may be even more significant in the development of human cancers, compared to the activation of oncogenes.
A brain tumor occurs when a group of cells within the brain turn cancerous and grow out of control, creating a mass. There are two main types of tumors: malignant (cancerous) tumors and benign (non-cancerous) tumors. These can be further classified as primary tumors, which start within the brain, and secondary tumors, which most commonly have spread from tumors located outside the brain, known as brain metastasis tumors. All types of brain tumors may produce symptoms that vary depending on the size of the tumor and the part of the brain that is involved. Where symptoms exist, they may include headaches, seizures, problems with vision, vomiting and mental changes. Other symptoms may include difficulty walking, speaking, with sensations, or unconsciousness.
External beam radiation therapy (EBRT) is a form of radiotherapy that utilizes a high-energy collimated beam of ionizing radiation, from a source outside the body, to target and kill cancer cells. The radiotherapy beam is composed of particles, which are focussed in a particular direction of travel using collimators. Each radiotherapy beam consists of one type of particle intended for use in treatment, though most beams contain some contamination by other particle types.
Orthovoltage X-rays are produced by X-ray tubes operating at voltages in the 100–500 kV range, and therefore the X-rays have a peak energy in the 100–500 keV range. Orthovoltage X-rays are sometimes termed "deep" X-rays (DXR). They cover the upper limit of energies used for diagnostic radiography, and are used in external beam radiotherapy to treat cancer and tumors. They penetrate tissue to a useful depth of about 4–6 cm. This makes them useful for treating skin, superficial tissues, and ribs, but not for deeper structures such as lungs or pelvic organs. The relatively low energy of orthovoltage X-rays causes them to interact with matter via different physical mechanisms compared to higher energy megavoltage X-rays or radionuclide γ-rays, increasing their relative biological effectiveness.
Glioblastoma, previously known as glioblastoma multiforme (GBM), is the most aggressive and most common type of cancer that originates in the brain, and has a very poor prognosis for survival. Initial signs and symptoms of glioblastoma are nonspecific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. Symptoms often worsen rapidly and may progress to unconsciousness.
In medicine, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer. The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth; hence in minimal entry, exit, or scattered radiation dose to healthy nearby tissues.
Virotherapy is a treatment using biotechnology to convert viruses into therapeutic agents by reprogramming viruses to treat diseases. There are three main branches of virotherapy: anti-cancer oncolytic viruses, viral vectors for gene therapy and viral immunotherapy. These branches use three different types of treatment methods: gene overexpression, gene knockout, and suicide gene delivery. Gene overexpression adds genetic sequences that compensate for low to zero levels of needed gene expression. Gene knockout uses RNA methods to silence or reduce expression of disease-causing genes. Suicide gene delivery introduces genetic sequences that induce an apoptotic response in cells, usually to kill cancerous growths. In a slightly different context, virotherapy can also refer more broadly to the use of viruses to treat certain medical conditions by killing pathogens.
In radiotherapy, radiation treatment planning (RTP) is the process in which a team consisting of radiation oncologists, radiation therapist, medical physicists and medical dosimetrists plan the appropriate external beam radiotherapy or internal brachytherapy treatment technique for a patient with cancer.
Particle therapy is a form of external beam radiotherapy using beams of energetic neutrons, protons, or other heavier positive ions for cancer treatment. The most common type of particle therapy as of August 2021 is proton therapy.
Bilikere Srinivasa Rao Dwarakanath is a molecular biologist and a radiation biologist, working on 2-Deoxy-D-glucose therapy in cancer research. His current research interests are experimental oncology, radiobiology, biological radioprotection and cell signaling in cancer therapy. He is currently the Joint Director of the Institute of Nuclear Medicine and Allied Sciences (INMAS), DRDO, Head, Division of Radiation Biosciences, INMAS, and Adjunct Faculty at the Dr. B. R. Ambedkar Center for Biomedical Research (ACBR), University of Delhi.
Arnold Jay Levine is an American molecular biologist. He was awarded the 1998 Louisa Gross Horwitz Prize for Biology or Biochemistry and was the first recipient of the Albany Medical Center Prize in Medicine and Biomedical Research in 2001 for his discovery of the tumor suppressor protein p53.
Cancer Breakthroughs 2020, also known as Cancer Moonshot 2020 is a coalition with the goal of finding vaccine-based immunotherapies against cancer. By pooling the resources of multinational pharmaceutical, biotechnology companies, academic centers and oncologists, it intends to create access to over 60 novel and approved agents under exploration in the war against cancer and is expected to enable rapid testing of novel immunotherapy combination protocols. The initiative is being managed by a consortium of companies called The National Immunotherapy Coalition.
Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research on T cell therapies for the treatment of several forms of cancers. In 2020 he was elected to the American Philosophical Society.
Guillermina 'Gigi' Lozano is an American geneticist. She is a Professor and Hubert L. Olive Stringer Distinguished Chair in Oncology in Honor of Sue Gribble Stringer at the University of Texas MD Anderson Cancer Center, Houston, Texas. Lozano is recognised for her studies of the p53 tumour suppressor pathway, characterising the protein as a regulator of gene expression and that is disturbed in many cancers. She was the first to recognize that the p53 gene encoded a transcriptional activator of other genes Her lab has made significant contributions by developing and analyzing mouse models to study the activities of mutant p53, revealing how these mutations drive tumor development and progression. She also found out how the Mdm2 and Mdm4 proteins work in the body, especially in stopping cancer and controlling p53. This research suggested that blocking Mdm2/4 could be a new way to treat cancer.
Andrzej Piotr Świerniak is a Polish mathematician, specializing in bioinformatics and control theory.
The laboratory mouse has been instrumental in investigating the genetics of human disease, including cancer, for over 110 years. The laboratory mouse has physiology and genetic characteristics very similar to humans providing powerful models for investigation of the genetic characteristics of disease.
A living medicine is a type of biologic that consists of a living organism that is used to treat a disease. This usually takes the form of a cell or a virus that has been genetically engineered to possess therapeutic properties that is injected into a patient. Perhaps the oldest use of a living medicine is the use of leeches for bloodletting, though living medicines have advanced tremendously since that time.
Emily S. Day is an American biomedical engineer. She is an associate professor at the University of Delaware where her research team engineers nanoparticles to enable high precision therapy of diseases including cancers, blood disorders, and maternal/fetal health complications.
Stacey Finley is the Nichole A. and Thuan Q. Pham Professor and associate professor of chemical engineering and materials science, and quantitative and computational biology at the University of Southern California. Finley has a joint appointment in the department of chemical engineering and materials science, and she is a member of the USC Norris Comprehensive Cancer Center. Finley is also a standing member of the MABS Study Section at NIH. Her research has been supported by grants from the NSF, NIH, and American Cancer Society.
